{"entity":{"type":"insider","cik":"0001674324","url":"/insider/0001674324","json_url":"/insider/0001674324.json","name":"5AM Ventures V, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":36,"n_filings":19,"first":"2019-10-31","last":"2026-08-10","span_basis":"filed_date"},"name_variants":[{"name":"5AM Ventures V, L.P.","source":"filing","n_filings":19,"first_seen":"2019-10-31","last_seen":"2026-08-10"}],"transactions":[{"id":9276041,"accession":"0001231919-26-000854","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000854","line_url":"/filing/0001231919-26-000854#line-2","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; 5AM Opportunities I, L.P.; 5AM Partners V, LLC; 5AM Ventures V, L.P.; ROCKLAGE SCOTT M; Schwab Andrew J.","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":52317.0,"shares_display":"52,317","price_per_share":6.85,"price_display":"6.85","price_state":"stated","total_value":358371.45,"total_display":"358,371.45","total_whole":"358,371","shares_owned_after":2783781.0,"shares_owned_after_display":"2,783,781","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-07","filed_date":"2026-08-10","scope":"insider"},{"id":9276042,"accession":"0001231919-26-000854","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000854","line_url":"/filing/0001231919-26-000854#line-1","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; 5AM Opportunities I, L.P.; 5AM Partners V, LLC; 5AM Ventures V, L.P.; ROCKLAGE SCOTT M; Schwab Andrew J.","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10494.0,"shares_display":"10,494","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":73458.0,"total_display":"73,458.00","total_whole":"73,458","shares_owned_after":2836098.0,"shares_owned_after_display":"2,836,098","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-06","filed_date":"2026-08-10","scope":"insider"},{"id":6042474,"accession":"0001231919-26-000822","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000822","line_url":"/filing/0001231919-26-000822#line-2","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"ROCKLAGE SCOTT M; 5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.","owner_display_name":"ROCKLAGE SCOTT M","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1718.0,"shares_display":"1,718","price_per_share":6.85,"price_display":"6.85","price_state":"stated","total_value":11768.3,"total_display":"11,768.30","total_whole":"11,768","shares_owned_after":2846592.0,"shares_owned_after_display":"2,846,592","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-31","filed_date":"2026-08-03","scope":"insider"},{"id":6042470,"accession":"0001231919-26-000822","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000822","line_url":"/filing/0001231919-26-000822#line-1","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"ROCKLAGE SCOTT M; 5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.","owner_display_name":"ROCKLAGE SCOTT M","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":114756.0,"shares_display":"114,756","price_per_share":6.93,"price_display":"6.93","price_state":"stated","total_value":795259.08,"total_display":"795,259.08","total_whole":"795,259","shares_owned_after":2848310.0,"shares_owned_after_display":"2,848,310","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-30","filed_date":"2026-08-03","scope":"insider"},{"id":5120377,"accession":"0001231919-25-000522","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-25-000522","line_url":"/filing/0001231919-25-000522#line-1","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; Schwab Andrew J.; ROCKLAGE SCOTT M","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200000.0,"shares_display":"200,000","price_per_share":8.8,"price_display":"8.80","price_state":"stated","total_value":1760000.0,"total_display":"1,760,000.00","total_whole":"1,760,000","shares_owned_after":2963066.0,"shares_owned_after_display":"2,963,066","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-14","filed_date":"2025-11-18","scope":"insider"},{"id":4953009,"accession":"0001415889-25-019677","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-019677","line_url":"/filing/0001415889-25-019677","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; 5AM Opportunities I, L.P.; 5AM Partners V, LLC; ROCKLAGE SCOTT M; Schwab Andrew J.","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27000.0,"shares_display":"27,000","price_per_share":7.502,"price_display":"7.50","price_state":"stated","total_value":202554.0,"total_display":"202,554.00","total_whole":"202,554","shares_owned_after":3163066.0,"shares_owned_after_display":"3,163,066","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-09","filed_date":"2025-07-11","scope":"insider","n_lines":2},{"id":4320273,"accession":"0001415889-25-018822","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-25-018822","line_url":"/filing/0001415889-25-018822","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; ROCKLAGE SCOTT M","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":7.1226,"price_display":"7.12","price_state":"stated","total_value":178065.0,"total_display":"178,065.00","total_whole":"178,065","shares_owned_after":3183131.0,"shares_owned_after_display":"3,183,131","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-01","filed_date":"2025-07-01","scope":"insider","n_lines":2},{"id":4320263,"accession":"0001415889-25-018822","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-25-018822","line_url":"/filing/0001415889-25-018822","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; ROCKLAGE SCOTT M","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":6.8127,"price_display":"6.81","price_state":"stated","total_value":170317.5,"total_display":"170,317.50","total_whole":"170,318","shares_owned_after":3201709.0,"shares_owned_after_display":"3,201,709","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-30","filed_date":"2025-07-01","scope":"insider","n_lines":2},{"id":4320250,"accession":"0001415889-25-018822","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-018822","line_url":"/filing/0001415889-25-018822","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; ROCKLAGE SCOTT M","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":75000.0,"shares_display":"75,000","price_per_share":6.91,"price_display":"6.91","price_state":"stated","total_value":518250.0,"total_display":"518,250.00","total_whole":"518,250","shares_owned_after":3220287.0,"shares_owned_after_display":"3,220,287","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-27","filed_date":"2025-07-01","scope":"insider","n_lines":2},{"id":7897039,"accession":"0001209191-23-017533","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-017533","line_url":"/filing/0001209191-23-017533#line-1","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Rallybio Corp","issuer_ticker":"RLYB","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Partners V, LLC; ROCKLAGE SCOTT M; 5AM Ventures V, L.P.; Schwab Andrew J.","owner_display_name":"5AM Partners V, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":8.2,"price_display":"8.20","price_state":"stated","total_value":820000.0,"total_display":"820,000.00","total_whole":"820,000","shares_owned_after":2378969.0,"shares_owned_after_display":"2,378,969","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-03-07","filed_date":"2023-03-09","scope":"insider"},{"id":6630807,"accession":"0001209191-22-034858","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-034858","line_url":"/filing/0001209191-22-034858","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Rallybio Corp","issuer_ticker":"RLYB","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Ventures V, L.P.; ROCKLAGE SCOTT M; Schwab Andrew J.; 5AM Opportunities I (GP), LLC; 5AM Opportunities I, L.P.; 5AM Partners V, LLC","owner_display_name":"5AM Ventures V, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":150000.0,"shares_display":"150,000","price_per_share":12.5,"price_display":"12.50","price_state":"stated","total_value":1875000.0,"total_display":"1,875,000.00","total_whole":"1,875,000","shares_owned_after":2478969.0,"shares_owned_after_display":"2,478,969","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-06-03","filed_date":"2022-06-07","scope":"insider","n_lines":2},{"id":6105225,"accession":"0001209191-22-031966","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-031966","line_url":"/filing/0001209191-22-031966","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Rallybio Corp","issuer_ticker":"RLYB","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"ROCKLAGE SCOTT M; 5AM Opportunities I (GP), LLC; 5AM Ventures V, L.P.; Schwab Andrew J.; 5AM Opportunities I, L.P.; 5AM Partners V, LLC","owner_display_name":"ROCKLAGE SCOTT M","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":1300000.0,"total_display":"1,300,000.00","total_whole":"1,300,000","shares_owned_after":2578640.0,"shares_owned_after_display":"2,578,640","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-05-23","filed_date":"2022-05-25","scope":"insider","n_lines":2},{"id":6388350,"accession":"0001209191-22-008584","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-008584","line_url":"/filing/0001209191-22-008584","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Rallybio Corp","issuer_ticker":"RLYB","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Partners V, LLC; ROCKLAGE SCOTT M; 5AM Opportunities I (GP), LLC; 5AM Ventures V, L.P.; Schwab Andrew J.; 5AM Opportunities I, L.P.","owner_display_name":"5AM Partners V, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":210000.0,"shares_display":"210,000","price_per_share":13.05,"price_display":"13.05","price_state":"stated","total_value":2740500.0,"total_display":"2,740,500.00","total_whole":"2,740,500","shares_owned_after":2645087.0,"shares_owned_after_display":"2,645,087","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-02-08","filed_date":"2022-02-10","scope":"insider","n_lines":2},{"id":5055362,"accession":"0001209191-21-063040","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-21-063040","line_url":"/filing/0001209191-21-063040#line-6","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Ventures V, L.P.; 5AM Opportunities I, L.P.; 5AM Opportunities I (GP), LLC; Schwab Andrew J.; ROCKLAGE SCOTT M; 5AM Partners V, LLC","owner_display_name":"5AM Ventures V, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":250000.0,"shares_display":"250,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":1132357.0,"shares_owned_after_display":"1,132,357","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-11-02","filed_date":"2021-11-04","scope":"insider"},{"id":5406317,"accession":"0001209191-21-062716","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-062716","line_url":"/filing/0001209191-21-062716","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Cabaletta Bio, Inc.","issuer_ticker":"CABA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Ventures V, L.P.; PARMAR KUSH; 5AM Partners V, LLC; 5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Opportunities I, L.P.; ROCKLAGE SCOTT M","owner_display_name":"5AM Ventures V, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":295000.0,"shares_display":"295,000","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":3835000.0,"total_display":"3,835,000.00","total_whole":"3,835,000","shares_owned_after":1731119.0,"shares_owned_after_display":"1,731,119","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-11-01","filed_date":"2021-11-03","scope":"insider","n_lines":2},{"id":5295081,"accession":"0001209191-21-055343","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-055343","line_url":"/filing/0001209191-21-055343#line-1","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Cabaletta Bio, Inc.","issuer_ticker":"CABA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Ventures V, L.P.; Schwab Andrew J.; PARMAR KUSH; ROCKLAGE SCOTT M; 5AM Opportunities I, L.P.; 5AM Partners V, LLC; 5AM Opportunities I (GP), LLC","owner_display_name":"5AM Ventures V, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":625000.0,"shares_display":"625,000","price_per_share":9.7,"price_display":"9.70","price_state":"stated","total_value":6062500.0,"total_display":"6,062,500.00","total_whole":"6,062,500","shares_owned_after":1989575.0,"shares_owned_after_display":"1,989,575","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-07","filed_date":"2021-09-09","scope":"insider"},{"id":5252228,"accession":"0001209191-21-049821","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-049821","line_url":"/filing/0001209191-21-049821#line-1","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Rallybio Corp","issuer_ticker":"RLYB","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; ROCKLAGE SCOTT M; 5AM Ventures V, L.P.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; Schwab Andrew J.","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":615384.0,"shares_display":"615,384","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":7999992.0,"total_display":"7,999,992.00","total_whole":"7,999,992","shares_owned_after":1406098.0,"shares_owned_after_display":"1,406,098","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-02","filed_date":"2021-08-04","scope":"insider"},{"id":4825537,"accession":"0001209191-21-029136","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-21-029136","line_url":"/filing/0001209191-21-029136#line-6","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"IMPEL NEUROPHARMA INC","issuer_ticker":"IMPL","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"ROCKLAGE SCOTT M; 5AM Opportunities I (GP), LLC; 5AM Ventures V, L.P.; Schwab Andrew J.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; PARMAR KUSH","owner_display_name":"ROCKLAGE SCOTT M","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":575000.0,"shares_display":"575,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":8625000.0,"total_display":"8,625,000.00","total_whole":"8,625,000","shares_owned_after":575000.0,"shares_owned_after_display":"575,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-04-27","filed_date":"2021-04-29","scope":"insider"},{"id":4923802,"accession":"0001209191-21-003268","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-003268","line_url":"/filing/0001209191-21-003268","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Cabaletta Bio, Inc.","issuer_ticker":"CABA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Ventures V, L.P.; 5AM Partners V, LLC; ROCKLAGE SCOTT M; PARMAR KUSH; 5AM Opportunities I, L.P.; 5AM Opportunities I (GP), LLC; Schwab Andrew J.","owner_display_name":"5AM Ventures V, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":85000.0,"shares_display":"85,000","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":1105000.0,"total_display":"1,105,000.00","total_whole":"1,105,000","shares_owned_after":2614575.0,"shares_owned_after_display":"2,614,575","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-01-12","filed_date":"2021-01-12","scope":"insider","n_lines":2},{"id":4923794,"accession":"0001209191-21-003268","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-003268","line_url":"/filing/0001209191-21-003268","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Cabaletta Bio, Inc.","issuer_ticker":"CABA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Ventures V, L.P.; 5AM Partners V, LLC; ROCKLAGE SCOTT M; PARMAR KUSH; 5AM Opportunities I, L.P.; 5AM Opportunities I (GP), LLC; Schwab Andrew J.","owner_display_name":"5AM Ventures V, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":302000.0,"shares_display":"302,000","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":3926000.0,"total_display":"3,926,000.00","total_whole":"3,926,000","shares_owned_after":2689045.0,"shares_owned_after_display":"2,689,045","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-01-08","filed_date":"2021-01-12","scope":"insider","n_lines":2},{"id":2480151,"accession":"0001209191-20-065778","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-065778","line_url":"/filing/0001209191-20-065778","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Akouos, Inc.","issuer_ticker":"AKUS","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"ROCKLAGE SCOTT M; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; Schwab Andrew J.; 5AM Ventures V, L.P.; 5AM Opportunities I (GP), LLC","owner_display_name":"ROCKLAGE SCOTT M","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":470000.0,"shares_display":"470,000","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":8460000.0,"total_display":"8,460,000.00","total_whole":"8,460,000","shares_owned_after":3153331.0,"shares_owned_after_display":"3,153,331","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-29","filed_date":"2020-12-31","scope":"insider","n_lines":2},{"id":3325549,"accession":"0001209191-20-063298","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-063298","line_url":"/filing/0001209191-20-063298","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Cabaletta Bio, Inc.","issuer_ticker":"CABA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; 5AM Opportunities I, L.P.; 5AM Partners V, LLC; PARMAR KUSH; ROCKLAGE SCOTT M; Schwab Andrew J.; 5AM Ventures V, L.P.","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":298000.0,"shares_display":"298,000","price_per_share":14.75,"price_display":"14.75","price_state":"stated","total_value":4395500.0,"total_display":"4,395,500.00","total_whole":"4,395,500","shares_owned_after":2953634.0,"shares_owned_after_display":"2,953,634","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-10","filed_date":"2020-12-14","scope":"insider","n_lines":2},{"id":3167016,"accession":"0001209191-20-040794","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-20-040794","line_url":"/filing/0001209191-20-040794#line-5","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Akouos, Inc.","issuer_ticker":"AKUS","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I, L.P.; ROCKLAGE SCOTT M; 5AM Opportunities I (GP), LLC; 5AM Ventures V, L.P.; 5AM Partners V, LLC; Schwab Andrew J.","owner_display_name":"5AM Opportunities I, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":294117.0,"shares_display":"294,117","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":4999989.0,"total_display":"4,999,989.00","total_whole":"4,999,989","shares_owned_after":1094101.0,"shares_owned_after_display":"1,094,101","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-06-30","filed_date":"2020-07-02","scope":"insider"},{"id":8116053,"accession":"0001104659-19-058504","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-19-058504","line_url":"/filing/0001104659-19-058504#line-2","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Cabaletta Bio, Inc.","issuer_ticker":"CABA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"PARMAR KUSH; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; 5AM Ventures V, L.P.; ROCKLAGE SCOTT M; 5AM Opportunities I (GP), LLC; Schwab Andrew J.","owner_display_name":"PARMAR KUSH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":454545.0,"shares_display":"454,545","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":4999995.0,"total_display":"4,999,995.00","total_whole":"4,999,995","shares_owned_after":454545.0,"shares_owned_after_display":"454,545","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-10-29","filed_date":"2019-10-31","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001689375","name":"Entrada Therapeutics, Inc.","url":"/issuer/0001689375","role":"Ten percent owner","n_filings":6,"first_seen":"2021-11-04","last_seen":"2026-08-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001739410","name":"Rallybio Corp","url":"/issuer/0001739410","role":"Ten percent owner","n_filings":5,"first_seen":"2021-08-04","last_seen":"2023-03-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001759138","name":"Cabaletta Bio, Inc.","url":"/issuer/0001759138","role":"Ten percent owner","n_filings":5,"first_seen":"2019-10-31","last_seen":"2021-11-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001445499","name":"IMPEL NEUROPHARMA INC","url":"/issuer/0001445499","role":"Ten percent owner","n_filings":1,"first_seen":"2021-04-29","last_seen":"2021-04-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001722271","name":"Akouos, Inc.","url":"/issuer/0001722271","role":"Ten percent owner","n_filings":2,"first_seen":"2020-07-02","last_seen":"2020-12-31"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001674324","retrieved_at":"2026-08-22T10:35:26+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}